Neurocrine to buy Soleno Therapeutics for $2.9 billion

Reuters

Mon, April 6, 2026 astatine 6:12 AM CDT 1 min read

April 6 (Reuters) - Neurocrine Biosciences volition get uncommon illness drugmaker ‌Soleno Therapeutics for $2.9 cardinal successful ‌cash, the companies said connected Monday, marking ​the neuroscience-focused drugmaker's enlargement into metabolic disorders.

Neurocrine has offered $53 per Soleno stock held, which represents a premium ‌of astir ⁠34% to stock's past close.

Soleno shares, which had risen ⁠more than 30% successful premarket trading aft the Financial Times archetypal ​reported the ​news, were ​halted.

The woody gives ‌Neurocrine entree to Vykat XR, the archetypal cause approved successful the U.S. to dainty hyperphagia associated with Prader-Willi syndrome, a uncommon familial disorder.

Hyperphagia, ‌or feelings of ​intense and persistent ​hunger, is ​the hallmark grounds of ‌Prader-Willi syndrome and tin ​lead to ​severe obesity arsenic good arsenic physical, intelligence and behavioural problems.

(Reporting ​by Gnaneshwar ‌Rajan and Mariam Sunny successful ​Bengaluru; Editing by Vijay Kishore ​and Sriraj Kalluvila)